Review

Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review

Min Ho Lee 1,†, Jae Il Shin 2,†, Jae Won Yang 3,†, Keum Hwa Lee 2, Do Hyeon Cha 1,4, Jun Beom Hong 1,   
Yeoeun Park 1, Eugene Choi 1, Kalthoum Tizaoui 5, Ai Koyanagi 6,7, Louis Jacob 6,8, Seoyeon Park 1, Ji Hong Kim 9,\* and Lee Smith 10

1 Yonsei University College of Medicine, Seoul, Korea; mhlee164@naver.com (M.H.L.);   
eric1@kaist.ac.kr (D.H.C.); bigjbh2@naver.com (J.B.H.); yeoeun@yonsei.ac.kr (Y.P.);   
4606347@naver.com (E.C.); harryme1713@yonsei.ac.kr (S.P.)

2 Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea;   
shinji@yuhs.ac (J.I.S.), AZSAGM@yuhs.ac (K.H.L.)

3 Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Korea;   
kidney74@yonsei.ac.kr

4 Graduate School of Medical Science and Engineering, Korea Advanced Institute for Science and Technology, Daejeon, Korea

5 Laboratory Microorganismes and Active Biomolecules, Sciences Faculty of Tunis,   
University Tunis El Manar, Tunis, Tunisia; kalttizaoui@gmail.com

6 Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain; a.koyanagi@pssjd.org (A.K.); louis.jacob.contacts@gmail.com (L.J.)

7 ICREA, Pg. LluisCompanys 23, Barcelona, Spain

8 Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France

9 Department of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine,   
Seoul, Korea

|  |
| --- |
| **Citation:** Lee, M.H.; Shin, J.I.; Yang, J.W.; Lee, K.H.; Cha, D.H.; Hong, J.B.; Park, Y.; Choi, E.; Tizaoui, K.; Koyanagi, A.; et al. Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review. *Int. J. Mol. Sci.* **2022**, *23*, x. https://doi.org/ 10.3390/xxxxx  Academic Editor(s): Amedeo Amedei  Received: 1 December 2021  Accepted: 30 December 2021  Published: date  **Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.    **Copyright:** © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |

10 The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK; Lee.Smith@aru.ac.uk

**\*** Correspondence: KKKJHD@yuhs.ac; Tel.: +82-2-2228-2050; Fax: +82-2-393-9118

† These authors contributed equally to this work.


**Abstract:** Autoimmune diseases are disorders that destruct or disrupt the body’s own tissues by its own immune system. Several studies have revealed that polymorphisms of multiple genes are involved in autoimmune diseases. Meanwhile, gene therapy has become a promising approach in autoimmune diseases, and Clustered Regularly Interspaced Palindromic Repeats and CRISPR-associated protein9 (CRISPR-Cas9) has become one of the most prominent methods. It has been shown that CRISPR-Cas9 can be applied to knock out Proprotein convertase subtilisin/kexin type 9 (PCSK9) or block PCSK9 resulting in lowering low-density lipoprotein cholesterol. In other studies, it can be used to treat rare diseases such as ornithine transcarbamylase (OTC) deficiency and hereditary tyrosinemia. However, limited studies on the treatment of autoimmune disease using CRISPR-Cas9 have been reported so far. In this review, we highlight the current and potential use of CRISPR-Cas9 in the management of autoimmune diseases. We summarize the potential target genes for immunomodulation using CRISPR-Cas9 in autoimmune diseases including rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type 1 diabetes mellitus (DM), psoriasis, and type 1 coeliac disease. This article will give a new perspective on understanding the use of CRISPR-Cas9 in autoimmune diseases not only through animal models but also in human models. Emerging approaches to investigate the potential target genes for CRISPR-Cas9 treatment may be promising for the tailored immunomodulation of some autoimmune diseases in the near future.

**Keywords:** CRISPR-Cas9; genome editing; autoimmune diseases


1. Introduction

Autoimmune disease is a disorder that destructs or disrupts the body’s own tissues by its own immune system [1]. Normally, the body’s immune system has immunologic tolerance so that it does not hurt its own body. However, in autoimmune disease, it attacks its own tissues and organs. Autoimmune diseases occur in up to 3–5% of the general population [1], and they decrease life expectancy. It has been shown that autoimmune diseases are associated with mood disorders [2] and impaired quality of life. Also it has been known that various genetic factors account for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes mellitus, and multiple sclerosis [3].

Meanwhile, gene therapy has become a promising approach as our understanding of the immunological and molecular basis of autoimmune diseases advanced [4]. The ultimate objective of gene therapy is regulation of the level of inflammatory cytokines and infiltration of lymphocytes to the affected sites (Figure 1) [4]. There has been a growing need for gene-editing therapeutic approaches, with Clustered Regularly Interspaced Palindromic Repeats and CRISPR-associated protein9 (CRIPSR-Cas9) being one of the most prominent methods [5]. CRISPR-Cas9, which has been widely renowned as genome-editing technology, is originally an adaptive immune system of bacteria and archaea and can be applicable in eukaryotic cells with single guide RNA (sgRNA) that contains complementary base sequence of a gene of interest [6]. By creating a synthetic sgRNA of a sequence complementary to a particular gene, Cas9, an RNA-guided DNA nuclease can knockout the gene (Figure 2) [7]. Gene knockout occurs during repair through non-homologous end joining (NHEJ) responding to the double strand breakage, in addition, knock-in can be performed via homologous direct recombination (HDR) if adequate template DNA is present [7,8]. The possibility of therapeutic application of CRISPR-Cas9 has been emerging based on various studies ranging from gene-editing in embryo with germline genetic variant to in vivo delivery in animal models of specific genetic diseases using viral or lipid vectors [5].



**Figure 1.** Treatment options for autoimmune disease.



**Figure 2.** The schematic diagram of CRISPR-Cas 9 in genomic engineering.

Application of CRISPR-Cas9 in genetic diseases has been reported in several investigations [9–15]. CRISPR-Cas9 can be applied to knock out Proprotein convertase subtilisinkexin type 9 (PCSK9) or block PCSK9 resulting in lowering low-density lipoprotein cholesterol [9,10]. Possibilities are not limited to frequently occurring diseases, and it holds great promise to treat rare diseases such as Ornithinetranscarbamylase (OTC) deficiency and hereditary tyrosinemia [11,12]. However, limited studies on the treatment of autoimmune disease using CRISPR-Cas9 have been reported so far. In this review, we highlight the current and potential use of CRISPR-Cas9 in the management of autoimmune diseases.

2. CRISPR-Cas9 and Autoimmune Diseases

2.1. In Vivo Therapeutic Trials Using CRISPR-Cas9

Autoimmunity usually occurs through systemic immune reaction caused by the failure to regulate the immune response adequately. For in vivo genetic correction via CRISPR-Cas9, sgRNA and Cas9 must be penetrated into the nucleus of the cell to edit the targeted DNA site. There are two major CRISPR-Cas9 delivery systems: viral vectors and lipid nanoparticles [5]. When using the viral transfer vector, adeno-associated virus (AAV), which has low possibility of genomic integration into foreign genes and has been demonstrated to be safe, is most widely used [16]. Because AAV is small in size, large-sized SpCas9 derived from Strepotococcus pyogenes is infrequently used despite its high efficacy, thus smaller Cas9 proteins derived from other bacterial species are used [17]. Cas9 derived from Staphylococcus aureus (SaCas9) or Campylobacter jejuni (CjCas9) can be packed together with sgRNA in AAV and applied to in vivo gene correction with a decent efficiency [18,19].

PCSK9, which regulates low-density lipoprotein (LDL) and is known as a major risk factor for atherosclerosis and coronary heart disease, was knocked-out in hepatocytes using NHEJ with SaCas9, resulting a significant decrease in LDL [20]. Another study reported that in vivo delivery of meganuclease with AAV targeting PCSK9 showed reduced levels of serum cholesterol [9,10]. Rare metabolic diseases have also been studied. A mouse model of OTC deficiency was treated with AAV8 and SaCas9, and a limited but significant therapeutic effect was observed in the management of hereditary tyrosinemia [11,12]. In some studies of Duchenne muscular dystrophy (DMD), the pathogenic mutation within exon23 was knocked out, and improvement in skeletal muscle and myocardial function was observed [13–15].

2.2. Inflammatory Molecules, Immunogenetics and CRISPR-Cas9

Autoimmunity is based on the simple concept of an imbalance between pro-inflammatory and anti-inflammatory stimuli, leading to an abnormal immune response. Cytokines like interleukin-1 (IL-1) and tumor necrosis factor (TNF) play an important role in inflammation, thus reducing the expression of these cytokines eventually leads to abrogation of the autoimmune process [21]. For example, interleukin-36 (IL-36) cytokines (IL-36A, IL-36B, and IL-36G) and members of the IL-1 family can cause pro-inflammatory effects in the skin and other organs [22]. Studies have shown that cytokines belonging to the IL-36 family may play an important role in the development of autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), sjögren’s syndrome, and psoriasis vulgaris [23–25]. Myeloid differentiation primary response gene 88(MyD88) adapter protein is known to be activated by IL-36 stimulation. Inactivation of MyD88 adapter protein by CRISPR-Cas9, reduced the activity of differentially expressed genes inducing the expression of IL-1B and IL-36G [26].

Tumor necrosis factor alpha-induced protein 3 (TNFAIP3), is induced by TNF-alpha and is known to inhibit NF-kappa B activation and TNF-mediated apoptosis [27]. The genetic variation of TNFAIP3 has been reported to be associated with susceptibility to develop SLE and RA [28,29]. In SLE, a genome-wide association study demonstrated that UBE2L3 could be a novel therapeutic target. UBE2L3 was identified as the key E2 enzyme for linear ubiquitin chain assembly complex (LUBAC) and essential for LUBAC-mediated activation of NF-kB [30]. In addition, association with familial Behçet-like auto inflammatory syndrome and infantile-onset intractable IBD was also reported [31,32]. A study on transcription activation-like effector nuclease (TALEN)-mediated knockout of TNFAIP3 demonstrated that correcting pathogenic TNFAIP3 variants can possibly reverse its related autoimmune phenotypes [33]. In addition, knockout of a candidate causal variant, rs6927172, by CRISPR-Cas9 gene editing influenced the expression of the IL-20RA and TNFAIP3 genes, potentially involved in the autoimmune response [34].

In addition to cytokines, many genetic variants that contribute to the development of autoimmune diseases are associated with T cells. For example, FoxP3 + regulatory T cells play an important role in immunological tolerance [35]. Immuno-dysregulation polyendocrinopathy, enteropathy X-linked (IPEX) syndrome caused by mutation of FoxP3 in humans can lead to a variety of autoimmune disorders in early childhood [36]. In IPEX, FoxP3 is decreased and the function of Tregs is remarkably degraded. In fact, epigenetic editing of the promoter and conserved non-coding sequence 2(CNS2) in the FoxP3 gene showed a 20–30% reduction in the effector T cell division [37] and thus CRISPR-Cas9 may be a potential therapeutic approach to manage IPEX cases.

2.3. CRISPR-Cas9 and iPSC

In autoimmunity, various treatment methods have been studied using CRISPR-Cas9. Induced pluripotent stem cells (iPSCs) were produced by adding interleukin-1 receptor antagonist (IL1Ra) or soluble TNF receptor gene by using CRISPR-Cas9 gene editing, and differentiated into articular cartilage. This showed that inflammatory response was attenuated by initiating dynamic negative feedback upon stimulation with inflammatory cytokines [38]. Other studies have reported that articular cartilage is resistant to IL-1alpha-mediated tissue degradation by the deletion of interleukin-1 receptor 1 (IL1r1) in murine iPSCs [39].

Gene editing in mesenchymal stem cells (MSCs) was utilized with CRISPR-Cas9 to target the endogenous activation of pancreatic transcription factors and MSC chemokine receptors. MSCs were differentiated into surrogate insulin producing cells, and may be transplanted through ex vivo expansion and transplantation while maintaining their immunomodulatory properties [40]. Other studies have successfully activated endogenous human insulin transcription using sgRNAs targeting multiple insulin promoter and a nuclease-deficient Cas9-virion protein 160 gene (dCas9-VP160) in human embryonic kidney 293 T cell (HEK293T), Hela, and human fibroblasts [41].

3. CRISPR-Cas9 and Rheumatoid Arthritis

Three studies tested genetic therapy in human cell models in RA. From these studies, the MYC, FOXO1 gene, SNP rs6927172, TNFAIP3, OLIG3 gene and miR-155 have been suggested as appropriate candidates for CRISPR-Cas9 treatment.

Yang et al. suggested that MYC and FOXO1 genes are associated with Rheumatoid arthritis [42]. It has been thought that in RA patients, CD4+ T-cells express higher autophagy and MYC was thought to be the regulator of the pathway [42]. FOXO1 has also been thought to be correlated with RA activity [42]. This study, by collecting ATAC-seq, Hi-C, Capture Hi-C and nuclear RNA-seq data in stimulated CD4+ T cells over 24 hours, provides evidence that MYC and FOXO1 genes may be causal factors of RA [42]. In the study by Yu et al., an intergenic SNP rs6927172 on chromosome 6q23 region was found to be associated with RA disease course according to a genome wide association study [43]. According to the study, many genes such as IL20RA, IL22RA2, IFNGR1, OLIG3, and TNFAIP3 flank the SNP area, and when they disrupt the SNP area using CRISPR-Cas9, only TNFAIP3 and OLIG3 showed decreased expressivity [43]. It shows that the SNP rs6927172, TNFAIP3 and OLIG3 are importantly associated with RA disease course [43]. Jing et al. demonstrated that micro RNA 155 (miR-155) could be an important pro-inflammatory factor in RA patients [44]. They used a miR-155 knock-out RAW 264.7 macrophage cell line and found that in the cell line, SHP1 was up-regulated and pro-inflammatory cytokine making process was impaired [44]. Thus they suggest that genome editing of miR-155 can be a potential therapeutic strategy for RA [44].

4. CRISPR-Cas9 and Inflammatory Bowel Disease

Four studies in human cell models and another four studies in mouse models tested genetic therapy in IBD. From these studies, JAK2, TL1A, SGK2, PTPN2, c-MYC, and HDAC7, and IFN- γ genes and miR-125a have been suggested as appropriate candidates for CRISPR-Cas9 treatment.

4.1. Studies on CRISPR-Cas9 and IBD Using Human Immune Cells

Analysis of rs1887428, located in the promoter region of the Janus kinase 2 [*JAK2*] gene, by Cardinale et al. revealed target genes affected by this polymorphism [45]. Authors found out that the risk allele of rs1887428 is bound by the transcription factor [TF] RBPJ [45]. According to the paper, rs1887428 did not have very large impacts on JAK2 expression but its impact was on STAT5B amplified downwards [45]. The limitation of this study was that it couldn’t find the TF binding motif and expression quantitative trait locus [45]. Mokhtar et al. demonstrated that the expression of SGK2 part of the PI3K/Akt pathway affects IBD disease course [46]. Immunohistochemistry was performed on SW480 cells and SGK2 gene knockdown was performed by CRISPR gRNA [46]. As a result, SGK2 protein was localized in the cytoplasm of colonic epithelial cells both in long and short duration ulcerative colitis [46]. This indicates that SGK2 gene may have a crucial role in IBD disease course [46]. In the study by Li et al., PTPN2 gene variants occured in Crohn’s disease patients.[46] In these patients, PTPN2 had loss of function mutation and it was associated with rs7234029 SNP.[46] They used subepithelial myelofibroblast cells(SEMF).[46] The result showed that PTPN2 expression was increased in the affected ileum compared to normal ileum and in contrast, CRISPR-Cas9 mediated PTPN2 deletion resulted in higher levels of STAT3 and Erk1/2 phosphorylation and proliferation [47]. It indicates that PTPN2 gene variants and SNP rs7234029 have a crucial role in Crohn’s disease [47]. Matthews et al. investigated rs6651252 SNP on chromosome 8 [48]. The study demonstrated that rs6651252 resides within a Wnt responsive DNA enhancer element and disease associated allele increases binding of the TCF7L2 transcription factor to the region [48]. Using CRISPR-Cas9, they found that rs6651252 enhancer regulates expression of the c-MYC, and they revealed that MYC expression levels are elevated in the Crohn’s disease patients [48].

4.2. Studies on CRISPR-Cas9 and IBD Using Non-Human Cells

Pai et al. focused on a Tumor necrosis factor super family member TL1A [49]. According to the study, spontaneous ileitis was present in TL1A transgenic mice [49]. When neutralizing anti-TL1A was used, brush border fanning and bacterial endocytosis caused by MLCK reduced [49]. Lastly, the expression of TL1A, IFNγ, and both MLCK1 and 2 was up-regulated in the mucosa of IBD patients. [48] Thus, the study demonstrates that the flare-up of TL1A, IFNγ, and MLCK is associated with IBD diseases course [49]. Friedrich et al. used primary colonic epithelial cells (CEC), human T84 and murine CMT93 to characterize functions of HDAC7 [50]. Knock-out mice were generated using CRISPR-Cas9 system [50]. The result showed that HDAC function was reduced in IBD patients, and according to the knock-out mice, HDAC was found to play a crucial role in maintenance of the intestinal barrier [50]. Eftychi et al. crossed NEMOIEC-KO with IFNγ -/- mice generated by CRISPR-Cas9 to demonstrate that IFN-γ can have a crucial role in colon inflammation [51]. They found that many pro-inflammatory cytokines such as Tnf, IL1b, and IL6 showed decreased expressivity in the knockout mice and suggested that IFN-γ is essential for colon inflammation [51]. Ge et al. showed that microRNA-125a can suppress intestinal mucosal inflammation [52]. According to their results, miR-125a expression was reduced in mucosa and peripheral blood of IBD patients [52]. MiR-125a suppresses Th1/Th17 cell differentiation and TNF-α production. In addition, miR-125a knockout mice showed more severe forms of colitis [52].

5. CRISPR-Cas9 and Systemic Lupus Erythematosus

Two studies tested genetic therapy in human cell models in SLE. From these studies, the A20 DUB and *CXorf21* gene have been suggested as appropriate candidates for CRISPR-Cas9 treatment. Odqvist et al. aimed to assess whether *TNFAIP3* (A20) de-ubiquitinase (DUB) increases the risk of SLE [53]. They used CRISPR-Cas9 to make human U937 monocytes with A20 DUB inactivating C103A knock-in mutation [53]. Results showed that A20 *C103A* cells or cells with rs2230926 polymorphism drew increased neutrophil extracellular trap and increased frequency of auto antibodies to citrullinated epitopes [53]. They concluded that interrupting the A20 DUB domain increases susceptibility to SLE [53]. Harris et al. focused on the involvement of Chromosome X open reading frame 21 *(CXorf21)* genes in SLE disease course [54]. They conducted in vitro CRISPR-Cas9 knockdown experiments and found that *CXorf21* knockdown resulted in a decreased expression of TNF-alpha and IL-6 [54]. They concluded that sexually dimorphic expression of CXorf21 could be a risk factor for SLE [54].

6. CRISPR-Cas9 and Multiple Sclerosis

Four studies tested genetic therapy in human cell models in MS. From these studies, the IR7R gene, the RNA helicase DEAD box polypeptide 39B, the IL2RA gene, and the TNFRSF1A gene have been suggested as appropriate candidates for CRISPR-Cas9 treatment. Gregory et al. demonstrated that the IL7Rα-related immune response pathway is crucial in the pathogenesis of MS [55]. The rs6897932 SNP in exon 6 of IL7R affects gene expression of the soluble versus membrane-bound form of the protein and increases the risk of MS [55]. The soluble form of IL7Rα is a driver of increased MS risk. The ‘C’ allele of rs6897932 is associated with MS and it enhances skipping of exon 6 of the IL7R gene by augmenting an exon splicing silencer [55]. The finding suggests that rs6897932 may affect the amount of the soluble versus membrane-bound form of the protein [55]. Isoforms are significant to regulate IL7 signaling pathway [55]. As a result, there is a direct relationship between alternative rs6897932 alleles and MS risk. Galarza-Munoz et al. demonstrated that human epistatic interaction is associated with MS risk. RNA helicase DDX39B, which is a potent activator of IL7R exon 6 and repressor of the soluble form of IL7R, strongly correlates with MS risk [56]. It was shown that epistatic interaction between rs2523506 in *DDX39B* and rs6897932 in IL7R regulates IL7R exon 6 splicing and increases risk of MS [56]. Not only local mutations in the IL7R gene, but genetic and functional epistasis with IR7R gene is related to the risk of MS. In another study, Maier et al. showed that the IL-2RA gene has many variants that increase the risk of MS and several variants were associated with sIL-2RA levels independently [57]. Maier et al. investigated IL-2RA genetic heterogeneity in MS and type 1 diabetes mellitus (T1DM) together, which are related to share alleles. IL2RA variants contributed to the risk of MS and T1DM respectively [57]. rs2104286 SNP located in intron 1 of IL2RA was mainly associated with susceptibility of MS [56]. Gregory et al. showed that TNF blocking agents are effective treatment options for non-MS autoimmune diseases. The investigation suggests that rs1800693 SNP in the TNFRSF1A gene, which encodes tumor necrosis factor receptor 1 (TNFR1), is associated with MS as the causal variant [58]. TNF blocking agents have side effects that promote the onset of MS and other autoimmune diseases such as RA. However, the study by Gregory et al. reported a disease signal for rs1800693 predictive of side effects [58].

7. CRISPR-Cas9 and Type 1 Diabetes Mellitus

One study tested genetic therapy in human cell models in Type 1 Diabetes mellitus (DM) and the other study tested this in mice models. From these studies, the AID/RAD51, and SNP rs10914542 of LCK gene have been suggested as appropriate candidates for CRISPR-Cas9 treatment. Zhu et al. attempted to reveal the role of SNPs of the Lymphocyte-specific protein tyrosine kinase (LCK) gene [59]. They gained blood samples from type 1 DM patients and used CRISPR-Cas9 to find the role of LCK SNP [59]. Among SNPs, only SNP rs10914542 showed meaningful association [59]. Thus, they demonstrate that G allele of rs10914542 SNP in LCK increases the risk of Type 1 DM [59]. Jeremy et al. used activation-induced cytidine deaminase (AID) gene knock-out mice and found that AID/RAD51 could be a target for treatment of Type 1 DM patients [60].

8. CRISPR-Cas9 and Psoriasis

One study tested genetic therapy in human cell models in psoriasis and the other study tested this in mouse models. From these studies, Desmoglein 1 and ERAP1 genes have been suggested as appropriate candidates for CRISPR-Cas9 treatment. Arakawa et al. demonstrated that ERAP1 has a crucial role in the development of psoriasis [61]. They generated ERAP1 knock-out melanoma cell line and revealed that epistasis between HLA-C\*06:02 and ERAP1 variants affect psoriasis [61]. The course includes ADAMTS-like protein 5 (ADAMTSL5) and immunogenicity of melanocytes [61]. Roth-Carter et al. used Desmoglein 1 knockout mice and found that the knockout mice exhibited barrier impairment [62]. Analysis of E18.5 skin of knockout mice revealed that inhibition of Dsg1 leads to increase in pathways to psoriatic process [62]. These results support a role of Dsg1 for differentiation of epidermis, formation of barriers, and regulation of inflammatory responses [62].

9. CRISPR-Cas9 and Type 1 Coeliac Disease

One study tested genetic therapy in cell models regarding coeliac disease [63]. From the study, the α- or γ-gliadin genes have been suggested as appropriate candidates for CRISPR-Cas9 treatment. According to Jouanin et al., wheat grains contain gluten proteins in which immunogenic epitopes can trigger coeliac disease [63]. They analyzed α- and γ-gliadin gene sequences and generated CRISPR-Cas9 constructs targeting α- or γ-gliadins [63]. The result showed that it is possible to use CRISPR-Cas9 to edit α- or γ-gliadins and make safe forms of grains [63].

10. Conclusions

In this study, we tried to widen our understanding of the role of CRISPR-Cas9 on the treatment of autoimmune diseases through a comprehensive review of literatures. We also reviewed target genes and SNPs of various autoimmune diseases manipulated by the CRISPR-Cas9 method. The review of target genes and SNPs is organized in Tables 1 and 2. As autoimmunity is based on an imbalance between pro-inflammatory and anti-inflammatory stimuli, cytokines such as IL1, IL36 and TNF alpha and T cell related factors are important in autoimmune diseases. By creating a synthetic sgRNA of a sequence complementary to a particular gene, Cas9, an RNA-guided DNA nuclease can knockout the genes related to the cytokines and T cell factors. Therefore, CRISPR-Cas9 may be a potential therapeutic approach to manage autoimmune diseases.

**Table 1.** Human cell models using CRISPR-Cas9 in autoimmune diseases.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Autoimmune Disease** | **Target Gene** | **SNP, miRNA** | **Results** | **Ref** |
| Yang et al., 2020 | RA | MYC, FOXO1 | - | By collecting ATAC-seq, Hi-C, Capture Hi-C and nuclear RNA-seq data in stimulated CD4+ T cells over 24 hours, the study provides evidence that MYC and FOXO1 genes may be causal factors of RA | [42] |
| Yu et al., 2016 | RA | IL20RA, IL22RA2, IFNGR1, OLIG3, TNFAIP3 | SNP rs6927172 | SNP rs6927172, TNFAIP3 and OLIG3 are importantly associated with the RA disease course | [43] |
| Jing et al., 2015 | RA | - | micro RNA 155 (miR-155) | Genome editing of miR-155 can be a potential therapeutic strategy for RA | [44] |
| Cardinale et al., 2020 | IBD | - | SNP rs1887428 | rs1887428 has not very large impacts on JAK2 expression but it impacts STAT5B downwards | [45] |
| Mokhtar et al., 2019 | IBD | SGK2 | - | SGK2 protein was localized in cytoplasm of colonic epithelial cells both in long and short duration ulcerative colitis | [46] |
| Li et al., 2018 | IBD | PTPN2 | SNP rs7234029 | PTPN2 expression was increased in affected ileum compared to normal ileum and in contrast, CRISPR-Cas9 mediated PTPN2 deletion resulted higher levels of STAT3 and Erk1/2 phosphorylation and proliferation | [47] |
| Matthews et al., 2019 | IBD | - | SNP rs6651252 | Using CRISPR-Cas9 they found that rs6651252 enhancer regulates expression of the c-MYC, and they also revealed that MYC expression levels are elevated in the Crohn’s disease patients | [48] |
| Odqvistet al., 2019 | SLE | TNFAIP3 | SNP rs2230926 | The result showed that A20 *C103A* cells or cells with rs2230926 polymorphism draw increased neutrophil extracellular trap and increased frequency of auto antibodies to citrullinated epitopes | [53] |
| Harris et al.l., 2019 | SLE | CXorf21 | - | They have done in vitro CRISPR-Cas9 knockdown experiments and found out that *CXorf21* knockdown resulted a decreased expression of TNF-alpha and IL-6 | [54] |
| Gregory et al., 2007 | MS | IL7R | SNP rs6897932 | There is a direct relationship between alternative rs6897932 alleles and MS risk | [55] |
| Galarza-Munoz et al., 2017 | MS | DDX39B | SNP rs2523506 | It was shown that epistatic interaction between rs2523506 in *DDX39B* and rs6897932 in IL7R regulates IL7R exon 6 splicing and increases risk of MS | [56] |
| Maier et al., 2009 | MS | IL-2RA | - | IL2RA variants contributed to the risk of MS and T1D respectively | [57] |
| Gregory et al., 2012 | MS | TNFRSF1A | SNP rs1800693 | TNF blocking agents have side effects that promote the onset of MS, when it is used in other autoimmune diseases such as RA, but this study found that a signal of disease association for rs1800693 is predictive of the side effect | [58] |
| Zhu et al., 2019 | T1DM | LCK | SNP rs10914542 | They demonstrated that G allele of SNP rs10914542 of LCK increases the risk of Type 1 DM | [59] |
| Arakawa et al., 2019 | Psoriasis | ERAP1 | - | They generated ERAP1 knock-out melanoma cell line and revealed that epistasis between HLA-C\*06:02 and ERAP1 variants will affect psoriasis. | [61] |
| Jouanin et al., 2019 | Coeliac disease | α- or γ-gliadin | - | The result showed that it is possible to use CRISPR-Cas9 to edit α- or γ-gliadins and make safe forms of grains | [63] |

Abbreviations—SNP: single nucleotide polymorphism; miRNA: micro ribonucleic acid; RNA: ribonucleic acid; RA: rheumatoid arthritis; SNP: single nucleotide polymorphism; IBD: inflammatory bowel disease; CRISPR-Cas9: Clustered regularly interspaced palindromic repeats and CRISPR-associated protein9; SLE: systemic lupus erythematosus; MS: multiple sclerosis; T1D: Type1 diabetes mellitus.

**Table 2.** Non-human cell models using CRISPR-Cas9 in autoimmune diseases.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Autoimmune Disease** | **Target Gene** | **SNP, miRNA** | **Results** | **Ref** |
| Pai et al., 2020 | IBD | TL1A | - | The flare-up of TL1A, IFNγ, and MLCK is associated with IBD diseases course | [49] |
| Friedrich et al., 2017 | IBD | HDAC7 | - | The result showed that HDAC function was reduced in IBD patients, and according to the knock-out mice, HDAC were found to play a crucial role in maintenance of the intestinal barrier | [50] |
| Eftychi et al., 2019 | IBD | IFN-γ | - | They found out that many pro-inflammatory cytokines such as TNF, IL1b, and IL6 showed decreased expressivity in the KO mice and suggested that IFN-γ is essential for colon inflammation | [51] |
| Ge et al., 2019 | IBD | - | miRNA-125a | MicroRNA-125a suppresses Th1/Th17 cell differentiation and TNF-α production. Also, miR-125a knock-out mice showed more severe forms of colitis | [52] |
| Ratiu et al., 2017 | T1DM | AID/RAD51 | - | AID/RAD51 can be a target for treatment of Type 1 DM patients | [60] |
| Roth-Carter et al., 2020 | Psoriasis | Desmoglein 1 | - | They supported a role of Dsg1 for differentiation of epidermis, formation of barriers, and regulation of inflammatory responses | [62] |

Abbreviations—IBD: inflammatory bowel disease; KO: knock out; T1DM: type 1 diabetes mellitus; Dsg1: desmoglein1.

Recently, gene therapy and especially CRISPR-Cas9 method has become a promising approach as our understanding of the immunological and molecular basis of autoimmune diseases advanced. Possibilities are not limited to frequently occurring diseases, but it even holds great promise to treat rare diseases. Nevertheless, many of the studies on the treatment of autoimmune diseases using CRISPR-Cas9 have been conducted in cell studies so far and therefore, more studies in humans are needed. Also, several technical challenges need to be addressed, such as off-target activity, insufficient indel or low homology-directed repair efficiency, in vivo delivery of the CRISPR-Cas9 system components, and immune responses [64]. Despite these limitations, the current evidence implies a promising role of CRISPR-Cas9 in the regulation of autoimmune diseases and further studies that focus on effectiveness of CRISPR-Cas9 method to human treatment are needed.

**Author Contributions:** All authors made substantial contributions to all of the following: conception and design of the study, J.I.S., J.H.K.; data acquisition, M.H.L., S.P., J.B.H., Y.P., E.C.; analysis, L.G.H., D.H.C., Y.K.; interpretation of data, A.K., L.J., S.M.; drafting or critical revision of the article for intellectual content, J.W.Y., J.I.S., K.K.H.; final approval of version to be submitted, J.W.Y., J.H.K., M.H.L. All authors have read and agreed to the published version of the manuscript

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Acknowledgments:** We express our sincere gratitude to the students at Yonsei University College of Medicine who assisted in the preparation of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

References

1. Marrack,P.;Kappler,J.;Kotzin,B.L.Autoimmunedisease:Whyandwhereitoccurs. *Nat. Med.* **2001**, *7*, 899–905. https://doi.org/10.1038/90935.
2. Benros,M.E.;Waltoft,B.L.;Nordentoft,M.;Ostergaard,S.D.;Eaton,W.W.;Krogh,J.;Mortensen,P.B.Autoimmunediseasesandsevereinfectionsasriskfactorsformooddisordersanationwidestudy. *JAMA Psychiatry* **2013**, *70*, 812–820. https://doi.org/10.1001/jamapsychiatry.2013.1111.
3. Cooper,G.S.;Miller,F.W.;Pandey,J.P.Theroleofgeneticfactorsinautoimmunedisease:Implicationsforenvironmentalresearch. *Environ. Health Perspect.* **1999**, *107* (Suppl. S5),693–700. https://doi.org/10.1289/ehp.99107s5693.
4. Shu,S.-A.;Wang,J.;Tao,M.-H.;Leung,P.S.C.Genetherapyforautoimmunedisease. *Clin. Rev. Allergy Immunol.* **2015**, *49*, 163–176. https://doi.org/10.1007/s12016-014-8451-x.
5. Yin,H.;Kauffman,K.J.;Anderson,D.G.Deliverytechnologiesforgenomeediting. *Nat. Rev. Drug Discov.* **2017**, *16*, 387–399. https://doi.org/10.1038/nrd.2016.280.
6. Gilbert,L.A.;Larson,M.H.;Morsut,L.;Liu,Z.;Brar,G.A.;Torres,S.E.;Stern-Ginossar,N.;Brandman,O.;Whitehead,E.H.;Doudna,J.A.; et al. Crispr-mediatedmodularrna-guidedregulationoftranscriptionineukaryotes. *Cell* **2013**, *154*, 442–451. https://doi.org/10.1016/j.cell.2013.06.044.
7. Doudna,J.A.;Charpentier,E.Genomeediting.Thenewfrontierofgenomeengineeringwithcrispr-cas9. *Science* **2014**, *346*, 1258096. https://doi.org/10.1126/science.1258096.
8. Hsu,P.D.;Lander,E.S.;Zhang,F.Developmentandapplicationsofcrispr-cas9forgenomeengineering. *Cell* **2014**, *157*, 1262–1278. https://doi.org/10.1016/j.cell.2014.05.010.
9. Ding,Q.;Strong,A.;Patel,K.M.;Ng,S.L.;Gosis,B.S.;Regan,S.N.;Cowan,C.A.;Rader,D.J.;Musunuru,K.Permanentalterationofpcsk9withinvivocrispr-cas9genomeediting. *Circ. Res.* **2014**, *115*, 488–492. https://doi.org/10.1161/CIRCRESAHA.115.304351.
10. Wang,L.;Smith,J.;Breton,C.;Clark,P.;Zhang,J.;Ying,L.;Che,Y.;Lape,J.;Bell,P.;Calcedo,R.*;* et al. Meganucleasetargetingofpcsk9inmacaqueliverleadstostablereductioninserumcholesterol. *Nat. Biotechnol.* **2018**, *36*, 717–725. https://doi.org/10.1038/nbt.4182.
11. Pankowicz,F.P.;Barzi,M.;Legras,X.;Hubert,L.;Mi,T.;Tomolonis,J.A.;Ravishankar,M.;Sun,Q.;Yang,D.;Borowiak,M.*;* et al. Reprogrammingmetabolicpathwaysinvivowithcrispr/cas9genomeeditingtotreathereditarytyrosinaemia. *Nat. Commun.* **2016**, *7*, 12642. https://doi.org/10.1038/ncomms12642.
12. Yang,Y.;Wang,L.;Bell,P.;McMenamin,D.;He,Z.;White,J.;Yu,H.;Xu,C.;Morizono,H.;Musunuru,K.*;* et al. Adualaavsystemenablesthecas9-mediatedcorrectionofametabolicliverdiseaseinnewbornmice. *Nat. Biotechnol.* **2016**, *34*, 334–338. https://doi.org/10.1038/nbt.3469.
13. Bengtsson,N.E.;Hall,J.K.;Odom,G.L.;Phelps,M.P.;Andrus,C.R.;Hawkins,R.D.;Hauschka,S.D.;Chamberlain,J.R.;Chamberlain,J.S.Muscle-specificcrispr/cas9dystrophingeneeditingamelioratespathophysiologyinamousemodelforduchennemusculardystrophy. *Nat. Commun.* **2017**, *8*, 14454. https://doi.org/10.1038/ncomms14454.
14. Mendell,J.R.;Rodino-Klapac,L.R.Duchennemusculardystrophy:Crispr/cas9treatment. *Cell Res.* **2016**, *26*, 513–514. https://doi.org/10.1038/cr.2016.28.
15. Nelson,C.E.;Hakim,C.H.;Ousterout,D.G.;Thakore,P.I.;Moreb,E.A.;CastellanosRivera,R.M.;Madhavan,S.;Pan,X.;Ran,F.A.;Yan,W.X.*;* et al. Invivogenomeeditingimprovesmusclefunctioninamousemodelofduchennemusculardystrophy. *Science* **2016**, *351*, 403–407. https://doi.org/10.1126/science.aad5143.
16. Daya,S.;Berns,K.I.Genetherapyusingadeno-associatedvirusvectors. *Clin. Microbiol. Rev.* **2008**, *21*, 583–593. https://doi.org/10.1128/CMR.00008-08.
17. Tycko,J.;Myer,V.E.;Hsu,P.D.Methodsforoptimizingcrispr-cas9genomeeditingspecificity. *Mol. Cell* **2016**, *63*, 355–370. https://doi.org/10.1016/j.molcel.2016.07.004.
18. Ran,F.A.;Cong,L.;Yan,W.X.;Scott,D.A.;Gootenberg,J.S.;Kriz,A.J.;Zetsche,B.;Shalem,O.;Wu,X.;Makarova,K.S.*;* et al. Invivogenomeeditingusingstaphylococcusaureuscas9. *Nature* **2015**, *520*, 186–191. https://doi.org/10.1038/nature14299.
19. Kim,E.;Koo,T.;Park,S.W.;Kim,D.;Kim,K.;Cho,H.Y.;Song,D.W.;Lee,K.J.;Jung,M.H.;Kim,S.*;* et al. Invivogenomeeditingwithasmallcas9orthologuederivedfromcampylobacterjejuni. *Nat Commun.* **2017**, *8*, 14500. https://doi.org/10.1038/ncomms14500.
20. Li,Q.;Su,J.;Liu,Y.;Jin,X.;Zhong,X.M.;Mo,L.;Wang,Q.N.;Deng,H.X.;Yang,Y.Invivopcsk9geneeditingusinganall-in-oneself-cleavageaav-crisprsystem. *Mol. Ther. -Methods Clin. Dev.* **2021**, *20*, 652–659. https://doi.org/10.1016/j.omtm.2021.02.005.
21. Dinarello,C.A.Interleukin-1andtumornecrosisfactor:Effectorcytokinesinautoimmunediseases. *Semin. Immunol.* **1992**, *4*, 133–145.
22. Garlanda,C.;Dinarello,C.A.;Mantovani,A.Theinterleukin-1family:Backtothefuture. *Immunity* **2013**, *39*, 1003–1018. https://doi.org/10.1016/j.immuni.2013.11.010.
23. Nishida,A.;Hidaka,K.;Kanda,T.;Imaeda,H.;Shioya,M.;Inatomi,O.;Bamba,S.;Kitoh,K.;Sugimoto,M.;Andoh,A.Increasedexpressionofinterleukin-36,amemberoftheinterleukin-1cytokinefamily,ininflammatoryboweldisease. *Inflamm. Bowel Dis.* **2016**, *22*, 303–314. https://doi.org/10.1097/MIB.0000000000000654.
24. Ciccia,F.;Accardo-Palumbo,A.;Alessandro,R.;Alessandri,C.;Priori,R.;Guggino,G.;Raimondo,S.;Carubbi,F.;Valesini,G.;Giacomelli,R.*;* et al. Interleukin-36alphaaxisismodulatedinpatientswithprimarysjogren’ssyndrome. *Clin. Exp. Immunol.* **2015**, *181*, 230–238. https://doi.org/10.1111/cei.12644.
25. Wang,M.;Wang,B.;Ma,Z.;Sun,X.;Tang,Y.;Li,X.;Wu,X.Detectionofthenovelil-1familycytokinesbyqah-il1f-1assayinrheumatoidarthritis. *Cell Mol. Biol.* **2016**, *62*, 31–34.
26. Swindell,W.R.;Beamer,M.A.;Sarkar.r,M.K.;Loftus,S.;Fullmer,J.;Xing,X.;Ward,N.L.;Tsoi,L.C.;Kahlenberg,M.J.;Liang,Y.; et al. Rna-seqanalysisofil-1bandil-36responsesinepidermalkeratinocytesidentifiesasharedmyd88-dependentgenesignature. *Front. Immunol.* **2018**, *9*, 80. https://doi.org/10.3389/fimmu.2018.00080.
27. Shembade,N.;Ma,A.;Harhaj,E.W.Inhibitionofnf-kappabsignalingbya20throughdisruptionofubiquitinenzymecomplexes. *Science* **2010**, *327*, 1135–1139. https://doi.org/10.1126/science.1182364.
28. Stahl,E.A.;Raychaudhuri,S.;Remmers,E.F.;Xie,G.;Eyre,S.;Thomson,B.P.;Li,Y.;Kurreeman,F.A.;Zhernakova,A.;Hinks,A.; et al. Genome-wideassociationstudymeta-analysisidentifiessevennewrheumatoidarthritisriskloci. *Nat. Genet.* **2010**, *42*, 508–514. https://doi.org/10.1038/ng.582.
29. Zhang,M.;Peng,L.L.;Wang,Y.;Wang,J.S.;Liu,J.;Liu,M.M.;Hu,J.;Song,B.;Yang,H.B.Rolesofa20inautoimmunediseases. *Immunol. Res.* **2016**, *64*, 337–344. https://doi.org/10.1007/s12026-015-8677-6.
30. Emil Bulatov, S.K.; Reis HJd Palotás, A.; Venkataraman, K.MookambeswaranVijayalakshmi&AlbertRizvanovUbiquitin-proteasomesystem:Promisingtherapeutictargetsinautoimmuneandneurodegenerativediseases. *BioNanoScience* **2016**, *6* 341–344. https://doi.org/10.1007/s12668-016-0233-x.
31. Zhou,Q.;Wang,H.;Schwartz,D.M.;Stoffels,M.;Park,Y.H.;Zhang,Y.;Yang,D.;Demirkaya,E.;Takeuchi,M.;Tsai,W.L.; et al. Loss-of-functionmutationsintnfaip3leadingtoa20haploinsufficiencycauseanearly-onsetautoinflammatorydisease. *Nat. Genet.* **2016**, *48*, 67–73. https://doi.org/10.1038/ng.3459.
32. Zheng,C.;Huang,Y.;Ye,Z.;Wang,Y.;Tang,Z.;Lu,J.;Wu,J.;Zhou,Y.;Wang,L.;Huang,Z.*;* et al. Infantileonsetintractableinflammatoryboweldiseaseduetonovelheterozygousmutationsintnfaip3(a20). *Inflamm. Bowel Dis.* **2018**, *24*, 2613–2620. https://doi.org/10.1093/ibd/izy165.
33. Wang,S.;Wen,F.;Tessneer,K.L.;Gaffney,P.M.Talen-mediatedenhancerknockoutinfluencestnfaip3geneexpressionandmimicsamolecularphenotypeassociatedwithsystemiclupuserythematosus. *Genes Immun.* **2016**, *17*, 165–170. https://doi.org/10.1038/gene.2016.4.
34. Wu,J.;Yang,S.;Yu,D.;Gao,W.;Liu,X.;Zhang,K.;Fu,X.;Bao,W.;Zhang,K.;Yu,J.*;* et al. Crispr/cas9mediatedknockoutofanintergenicvariantrs6927172identifiedil-20raasanewriskgeneformultipleautoimmunediseases. *Genes Immun.* **2018**, *20*, 103–111. https://doi.org/10.1038/s41435-018-0011-6.
35. Fontenot,J.D.;Rasmussen,J.P.;Williams,L.M.;Dooley,J.L.;Farr,A.G.;Rudensky,A.Y.Regulatorytcelllineagespecificationbytheforkheadtranscriptionfactorfoxp3. *Immunity* **2005**, *22*, 329–341. https://doi.org/10.1016/j.immuni.2005.01.016.
36. Bennett,C.L.;Christie,J.;Ramsdell,F.;Brunkow,M.E.;Ferguson,P.J.;Whitesell,L.;Kelly,T.E.;Saulsbury,F.T.;Chance,P.F.;Ochs,H.D.Theimmunedysregulation,polyendocrinopathy,enteropathy,x-linkedsyndrome(ipex)iscausedbymutationsoffoxp3. *Nat. Genet.* **2001**, *27*, 20–21. https://doi.org/10.1038/83713.
37. Jeffries,M.A.Epigeneticediting:Howcutting-edgetargetedepigeneticmodificationmightprovidenovelavenuesforautoimmunediseasetherapy. *Clin. Immunol.* **2018**, *196*, 49–58. https://doi.org/10.1016/j.clim.2018.02.001.
38. Brunger,J.M.;Zutshi,A.;Willard,V.P.;Gersbach,C.A.;Guilak,F.Genomeengineeringofstemcellsforautonomouslyregulated,closed-loopdeliveryofbiologicdrugs. *Stem Cell Rep.* **2017**, *8*, 1202–1213. https://doi.org/10.1016/j.stemcr.2017.03.022.
39. Brunger,J.M.;Zutshi,A.;Willard,V.P.;Gersbach,C.A.;Guilak,F.Crispr/cas9editingofmurineinducedpluripotentstemcellsforengineeringinflammation-resistanttissues. *Arthritis Rheumatol.* **2017**, *69*, 1111–1121. https://doi.org/10.1002/art.39982.
40. Gerace,D.;Martiniello-Wilks,R.;Nassif,N.T.;Lal,S.;Steptoe,R.;Simpson,A.M.Crispr-targetedgenomeeditingofmesenchymalstemcell-derivedtherapiesfortype1diabetes:Apathtoclinicalsuccess? *Stem Cell Res.* **2017**, *8*, 62. https://doi.org/10.1186/s13287-017-0511-8.
41. Gimenez,C.A.;Ielpi,M.;Mutto,A.;Grosembacher,L.;Argibay,P.;Pereyra-Bonnet,F.Crispr-onsystemfortheactivationoftheendogenoushumaninsgene. *Gene* **2016**, *23*, 543–547. https://doi.org/10.1038/gt.2016.28.
42. Yang,J.;McGovern,A.;Martin,P.;Duffus,K.;Ge,X.;Zarrineh,P.;Morris,A.P.;Adamson,A.;Fraser,P.;Rattray,M.; et al. Analysisofchromatinorganizationandgeneexpressionintcellsidentifiesfunctionalgenesforrheumatoidarthritis. *Nat. Commun.* **2020**, *11*, 4402. https://doi.org/10.1038/s41467-020-18180-7.
43. Yu,D.;Jin,Z.;Liu,X.;Gao,W.;Gao,X.;Zhang,S.;Ma,S.;Yu,J.;Wang,S.Manipulationofanra-associatedintergenicsnpbycrispr/cas9systemaltersexpressionofmultiplegenesatthetnfaip3locus,posterpresentationabstracts. *Int. J. Rheum. Dis.* **2016**, *19* (Suppl. S2),89. https://doi.org/10.1111/1756-185X.12962.
44. Jing,W.;Zhang,X.;Sun,W.;Hou,X.;Yao,Z.;Zhu,Y.Crispr/cas9-mediatedgenomeeditingofmirna-155inhibitsproinflammatorycytokineproductionbyraw264.7cells. *Biomed. Res. Int.* **2015**, *2015*, 326042. https://doi.org/10.1155/2015/326042.
45. Cardinale,C.J.;March,M.E.;Lin,X.;Liu,Y.;Spruce,L.A.;Bradfield,J.P.;Wei,Z.;Seeholzer,S.H.;Grant,S.F.A.;Hakonarson,H.Regulationofjanuskinase2byaninflammatoryboweldiseasecausalnon-codingsinglenucleotidepolymorphism. *J. Crohn’s Colitis* **2020**, *14*, 646–653. https://doi.org/10.1093/ecco-jcc/jjz213.
46. Mokhtar,N.;DenLow,E.N.;Yahaya,A.;Ali,R.A.R.Characterisationofsgk2geneusingcrispr/cas9geneeditingtoolinulcerativecolitis. *J. Gastroenterol. Hepatol.* **2019**, *34* (Suppl. S3),274. https://doi.org/10.1111/jgh.14879.
47. Li,C.;Kuemmerle,J.P119theroleofptpn2snpinthepathogenesisoffibrosisincrohn’sdisease. *Inflamm. Bowel Dis.* **2019**, *25*, S57-S58. https://doi.org/10.1093/ibd/izy393.130.
48. Matthews,S.M.;Eshelman,M.A.;Berg,A.S.;Koltun,W.A.;Yochum,G.S.Thecrohn’sdiseaseassociatedsnprs6651252impactsmycgeneexpressioninhumancolonicepithelialcells. *PLoS ONE* **2019**, *14*, e0212850. https://doi.org/10.1371/journal.pone.0212850.
49. Pai,Y.-C.;Shih,D.Q.;Targan,S.R.;Turner,J.;Wei,S.C.;Yu,L.C.H.Su1097tl1a-mediatedbacterialtranscytosisbyamlcksplicingvariantcontributestoinflammatoryboweldisease. *Gastroenterology* **2020**, *158*, S-508. https://doi.org/10.1016/S0016-5085(20)31949-1.
50. Friedrich,M.;Ganther,J.;Breiderhoff,T.;Rosenthal,R.;Glauben,R.;Siegmund,B.P063hdacasversatileregulatorsoftheintestinalepithelialbarrierininflammatoryboweldisease. *J. Crohn’s Colitis* **2017**, *11*, S109–S109. https://doi.org/10.1093/ecco-jcc/jjx002.189.
51. Eftychi,C.;Schwarzer,R.;Vlantis,K.;Wachsmuth,L.;Basic,M.;Wagle,P.;Neurath,M.F.;Becker,C.;Bleich,A.;Pasparakis,M.Temporallydistinctfunctionsofthecytokinesil-12andil-23drivechroniccoloninflammationinresponsetointestinalbarrierimpairment. *Immunity* **2019**, *51*, 367–380e364. https://doi.org/10.1016/j.immuni.2019.06.008.
52. Ge,Y.D.;Sun,M.M.;Wu,W.;Ma,C.Y.;Zhang,C.;He,C.;Li,J.X.;Cong,Y.Z.;Zhang,D.K.;Liu,Z.J.Microrna-125asuppressesintestinalmucosalinflammationthroughtargetingets-1inpatientswithinflammatoryboweldiseases. *J. Autoimmun.* **2019**, *101*, 109–120. https://doi.org/10.1016/j.jaut.2019.04.014.
53. Odqvist,L.;Jevnikar,Z.;Riise,R.;Oberg,L.;Rhedin,M.;Leonard,D.;Yrlid,L.;Jackson,S.;Mattsson,J.;Nanda,S.*;* et al. Geneticvariationsina20dubdomainprovideageneticlinktocitrullinationandneutrophilextracellulartrapsinsystemiclupuserythematosus. *Ann. Rheum. Dis.* **2019**, *78*, 1363–1370. https://doi.org/10.1136/annrheumdis-2019-215434.
54. Harris,V.M.;Koelsch,K.A.;Kurien,B.T.;Harley,I.T.W.;Wren,J.D.;Harley,J.B.;Scofield,R.H.Characterizationofcxorf21providesmolecularinsightintofemale-biasimmuneresponseinslepathogenesis. *Front. Immunol.* **2019**, *10*, 2160. https://doi.org/10.3389/fimmu.2019.02160.
55. Gregory,S.G.;Schmidt,S.;Seth,P.;Oksenberg,J.R.;Hart,J.;Prokop,A.;Caillier,S.J.;Ban,M.;Goris,A.;Barcellos,L.F.*;* et al. Interleukin7receptoralphachain(il7r)showsallelicandfunctionalassociationwithmultiplesclerosis. *Nat. Genet.* **2007**, *39*, 1083–1091. https://doi.org/10.1038/ng2103.
56. Galarza-Munoz,G.;Briggs,F.B.S.;Evsyukova,I.;Schott-Lerner,G.;Kennedy,E.M.;Nyanhete,T.;Wang,L.;Bergamaschi,L.;Widen,S.G.;Tomaras,G.D.*;* et al. Humanepistaticinteractioncontrolsil7rsplicingandincreasesmultiplesclerosisrisk. *Cell* **2017**, *169*, 72–84e13. https://doi.org/10.1016/j.cell.2017.03.007.
57. Maier,L.M.;Lowe,C.E.;Cooper,J.;Downes,K.;Anderson,D.E.;Severson,C.;Clark,P.M.;Healy,B.;Walker,N.;Aubin,C.; et al. Il2rageneticheterogeneityinmultiplesclerosisandtype1diabetessusceptibilityandsolubleinterleukin-2receptorproduction. *PLoS Genet.* **2009**, *5*, e1000322. https://doi.org/10.1371/journal.pgen.1000322.
58. Gregory,A.P.;Dendrou,C.A.;Attfield,K.E.;Haghikia,A.;Xifara,D.K.;Butter,F.;Poschmann,G.;Kaur,G.;Lambert,L.;Leach,O.A.*;* et al. Tnfreceptor1geneticriskmirrorsoutcomeofanti-tnftherapyinmultiplesclerosis. *Nature* **2012**, *488*, 508–511. https://doi.org/10.1038/nature11307.
59. Zhu,Q.;Wang,J.;Zhang,L.;Bian,W.;Lin,M.;Xu,X.;Zhou,X.Lckrs10914542-galleleassociateswithtype1diabetesinchildrenviatcellhyporesponsiveness. *Pediatr. Res.* **2019**, *86*, 311–315. https://doi.org/10.1038/s41390-019-0436-2.
60. Ratiu,J.J.;Racine,J.J.;Hasham,M.G.;Wang,Q.;Branca,J.A.;Chapman,H.D.;Zhu,J.;Donghia,N.;Philip,V.;Schott,W.H.; et al. Geneticandsmallmoleculedisruptionoftheaid/rad51axissimilarlyprotectsnonobesediabeticmicefromtype1diabetesthroughexpansionofregulatoryblymphocytes. *J. Immunol.* **2017**, *198*, 4255–4267. https://doi.org/10.4049/jimmunol.1700024.
61. Arakawa,A.;Vollmer,S.;Arakawa,Y.;He,M.;Reeves,E.;James,E.;Prinz,J. *Erap1 Regulates the Risk for Psoriasis through Affecting Immunogenicity of Melanocytes and the Psoriatic Autoantigen Adamts-Like Protein 5*, *Proceedings of the 46th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), Munich, Germany, 13–16 March 2019*;Wiley:Munich,Germany, 2019;pp.E66–E67.
62. Roth-Carter,Q.R.;Godsel,L.;Koetsier,J.L.;Broussard,J.A.;Burks,H.E.;Fitz,G.;Huffine,A.L.;Amagai,S.;Lloyd,S.;Kweon,J.*;* et al. 225desmoglein1deficiencyinknockoutmiceimpairsepidermalbarrierformationandresultsinapsoriasis-likegenesignatureine18.5embryos. *J. Investig. Dermatol.* **2020**, *140*, S26. https://doi.org/10.1016/j.jid.2020.03.230.
63. Jouanin,A.;Schaart,J.G.;Boyd,L.A.;Cockram,J.;Leigh,F.J.;Bates,R.;Wallington,E.J.;Visser,R.G.F.;Smulders,M.J.M.Outlookforcoeliacdiseasepatients:Towardsbreadwheatwithhypoimmunogenicglutenbygeneeditingofalpha-andgamma-gliadingenefamilies. *BMC Plant Biol.* **2019**, *19*, 333. https://doi.org/10.1186/s12870-019-1889-5.
64. Yang,Y.;Xu,J.;Ge,S.;Lai,L.Crispr/cas:Advances,limitations,andapplicationsforprecisioncancerresearch. *Front. Med.* **2021**, *8*. https://doi.org/10.3389/fmed.2021.649896.